INTRODUCTION
Infantile spasms (IS; West syndrome) is a rare (occurring in about 1.6-4.5/10,000 live births) [1] [2] [3] [4] , but often devastating form of epilepsy that typically occurs in the first year of life [2] . Although spasms usually resolve by age five, the long-term prognoses of infants diagnosed with IS are relatively poor, with the majority of patients developing conditions, such as refractory epilepsy, mental retardation, and autistic spectrum disorders [2, [5] [6] [7] [8] [9] . While the therapeutic response and complete resolution of IS largely depend on the underlying etiology and other clinical factors, early diagnosis and prompt treatment may improve neurological and developmental outcomes [2, 9, 10] .
In the US, hormonal therapies, such as intramuscular adrenocorticotropic hormone (ACTH), are commonly used to treat IS; a recent survey of clinicians treating IS reported that 84% prescribed ACTH [11] . However, only two drugs have received US Food and Drug Administration (FDA) approval to treat IS: the gamma-aminobutyric acid transaminase inhibitor vigabatrin (Sabril Ò ; Lundbeck) [12] and H.P. Acthar Ò Gel (repository corticotropin injection; Acthar; Mallinckrodt) [13] . Following treatment, infants typically undergo electroencephalograms (EEGs) to evaluate treatment effectiveness, which is defined as both complete cessation of spasms as well as the resolution of hypsarrhythmia on EEGs [2] and, if indicated, treatments are modified [5] .
Although analysis of healthcare resource utilization in patients with convulsive disorders is the starting point for economic assessment of the medical burden of these conditions, little research has been conducted. The purpose of this study was to describe health outcomes and costs resulting from early (within 30 days of diagnosis) prescriptions of Acthar versus later (more than 30 days after diagnosis) prescriptions to generate hypotheses for future studies on healthcare utilization and treatment patterns among patients with IS.
METHODS

Study Population and Data Source
We used the Truven Health MarketScan [14] .
Patients with subsequent diagnoses of tuberous sclerosis complex (TSC; ICD-9-CM diagnosis code: 759.5) were excluded from our analyses.
TSC is a complex genetic disorder that can affect multiple organs and is usually treated effectively with vigabatrin or surgery [15] . To have complete comorbidity and health outcome data, we also excluded patients who were not enrolled in their health plans continuously for at least 3 months prior and 12 months after the index date.
We classified patients in our study cohort Table S1 in the supplementary material for a complete list of these medications), previous diagnoses of major cardiac diseases, central nervous system malformations, and severe metabolic conditions (see Table S2 in the supplementary material for a complete list of the ICD-9-CM diagnosis codes included in each of these categories).
Statistical Analysis
We calculated proportions and Chi-square For the binary outcome of whether patients were readmitted to the hospital within 30 days of discharge, we used logistic regression to calculate odds ratios (ORs) and 99% CIs. For cost outcomes, we used generalized linear regressions with log links and specified the gamma distribution to calculate adjusted means and 99% CIs. To allow cost models to run, nominal amounts were added to patients with zero costs. Because the inclusion of covariates in the adjusted models affected the estimates of component costs, individual cost components did not add exactly to the adjusted total costs. SAS for Windows, version 9.3 (SAS Institute, Inc., Cary, NC, USA) was used for all analyses.
Compliance with Ethics Guidelines
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, revised in 2013.
This study was exempt from review by the
University of Washington Institutional Review
Board (IRB) through self-determination. Table 1 . A smaller proportion of early Acthar prescription recipients were female compared to male (39% versus 61%; P = 0.03). A higher proportion of patients who received Acthar later filled prescriptions for anticonvulsants prior to filling prescriptions for Acthar (21% versus 33%; P = 0.07). In addition, higher proportions of patients who received Acthar later had been diagnosed with severe central nervous system malformations prior to being diagnosed with IS (14% versus 31%; P = 0.002).
RESULTS
Out
Patients who were prescribed Acthar early had fewer hospitalizations in the 90 days prior to the IS diagnosis compared to patients who were prescribed Acthar later (0.2 versus 0.6; P = 0.0002). Patients who were prescribed Acthar early were similar to those who were prescribed Acthar later in terms of age, insurance plan, geographic region, and year of IS diagnosis, whether they filled prescriptions for steroids prior to filling prescriptions for Acthar, whether they had diagnoses of major cardiac diseases or metabolic conditions, and the number of outpatient services and 99% CI -6.7 to -0.7) as did the reduced number of total health services (4.2 fewer total health services; 99% CI -7.9 to -0.4). We also found that, among patients who had at least one hospitalization, those who received Acthar early were almost twice as likely to have been readmitted within 30 days, though not statistically significantly (99% CI 0.7 to 5.0). research has shown that earlier treatment is associated with improved developmental outcomes [10] . One study showed that earlier treatment for IS significantly improved patients' Vineland Adaptive Behavior Scale (VABS) scores, which measured patients' ability to cope with environmental changes, demonstrate independence, and learn new skills [16] . Another study indicated that neurodevelopmental outcomes are better for infants who have shorter duration of spasms and, therefore, shorter times of epileptic encephalopathy [17] . Our study contributes to evidence that earlier treatment for IS may also be beneficial to achieve less healthcare utilization and lower medication burden.
This study had several limitations. First, exposure to Acthar was predominantly identified through outpatient prescription fills, thus it is possible that some patients were subject to misclassification, because the medication was not actually administered.
However, given that Acthar is a brand name medication that is usually accompanied with a portion of patient cost-sharing, and that we observed patients with multiple prescription fills, we are reassured that the majority of patients with Acthar prescription claims actually received the medication. In addition, because this was an observational study and not a randomized control trial, we cannot be certain that the differences we observed between patients who were prescribed Acthar early versus later could not be explained by confounding factors. We attempted to correct for this by adjusting our models for potentially confounding variables, but unmeasured factors might play a role in the associations that we reported. Because we were interested in outcomes that occurred over the 12 months after the index IS diagnosis, we excluded patients who were not enrolled in their health plans for 1 year after the index event, so our population was stable by definition, and our results are likely not generalizable to more transient populations. We also did not have information on procedures or healthcare resource utilization for which patients paid out-of-pocket rather than filing claims through their insurance companies, and our cost estimates might, therefore, be conservative.
Furthermore, the population of patients in the MarketScan databases is not randomly sampled and some populations, such as patients insured by small employers, were not represented in this study population. Therefore, these results may not be generalizable across all patients with IS in the US. Finally, we were unable to account for potential lag times from initial IS symptoms until definitive diagnoses were observed in the Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval to the version to be published. All authors had full access to all of the data in this study and take complete responsibility for the integrity of the data and accuracy of the data analysis. 
